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Edited by Takashi GojoboriAbstract The transcription factor PU.1 plays an important
role in the development of the myeloid and lymphoid lineages and
regulates the transcription of several genes expressed in these
cells. Ser41 is conserved in the acidic region (33–47) of PU.1
from a variety of eukaryocytes and has been reported to be one
of the two important Ser residues (S41 and S45) for the function
of PU.1. In the present study, however, we found that rat PU.1
has Gly at position 41. To elucidate the role of amino acid
residues at 41 and 45 in functions of PU.1, we generated mutants
of rat PU.1, G41S, G41A, and S45A, and analyzed their
transcription-enhancing activities by using two diﬀerent systems,
transient reporter assay system and retroviral transfection
system. The amino acid substitution at 41 of PU.1 causes no
eﬀect on both transcription-enhancing activity for M-CSF
receptor promoter and the cooperative transcription-enhancing
activity with GATA-1 for FceRI a-chain promoter. Further-
more, the substitution at 41 also had no eﬀect on the activity to
induce monocyte-speciﬁc gene expression in the bone marrow-
derived hematopoietic cells. From these results, we conclude that
Ser41 as well as Ser45 are not essential for the promoter-
upregulating function of PU.1.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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PU.1, a transcription factor belonging to Ets-family, is
critically required for the development of both myeloid and
lymphoid lineages and the cell-type speciﬁc gene expression.
Necessity of PU.1 for generation of these lineages was deﬁni-
tively demonstrated by PU.1 gene disruption that abolishes
macrophages and B cells production and delays neutrophils
and T cells production [1–5]. According to the analysis using
truncation or amino acid replacement of PU.1, the function of
each domain has been elucidated; the acidic region and the
glutamine-rich region are both involved in transactivation, the* Corresponding author. Fax: +81-3-3813-5512.
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degradation [7], and the Ets domain in DNA-binding. In ad-
dition, it has been reported that Ser41 is also required for
AKT-induced transactivation of jE30-enhancer activity in B
cells [8] and both Ser residues at position 41 and 45 are in-
volved in macrophage proliferation [9]. These results suggest
that Ser residues at 41 and 45 are important for PU.1 functions
in these cells. We recently found that overexpression of PU.1 in
bone marrow-derived cells by retroviral transfection induced
the expression of monocyte-speciﬁc genes [10,11]. In the
analysis, the acidic region (from 33 to 73) was shown to be
essential for the induction [11]. Since both Ser residues are
contained in the acidic region, we at ﬁrst thought that the Ser
residues were necessary for the function of PU.1. In the present
study, however, we found that rat PU.1 possesses Gly but not
Ser as the 41st residue. This ﬁnding prompted us to examine
whether or not Ser41 is indeed necessary for the functions of
PU.1. In the present analysis, in addition to general transient
expression system using luciferase as the reporter, we used the
retroviral transfection system to evaluate the possible role of
Ser41 as well as Ser45. In this paper, we describe that Ser
residues at 41 and 45 are not essential for the functions of
PU.1.2. Materials and methods
2.1. Culture of cell lines
KU812 and U937 cells were cultured in RPMI 1640 medium (Sig-
ma–Aldrich, St. Louis, MO) supplemented with 10% FCS (Biological
Industries, Haemek, Israel), 100 U/ml penicillin, and 100 lg/ml
streptomycin. RBL-2H3 and CV-1 cells were grown in a-MEM (In-
vitrogen, San Diego, CA) and DMEM (Sigma–Aldrich, St. Louis,
MO) supplemented with 10% FCS, penicillin, and streptomycin, re-
spectively. Retrovirus packaging cell line, Plat-E [12], was maintained
in DMEM supplemented with 10% FCS, penicillin, streptomycin, 1 lg/
ml puromycin (Sigma–Aldrich), and 10 lg/ml blasticidin (Funakoshi,
Tokyo, Japan).
2.2. Cloning of rat PU.1 cDNA
Total RNA from RBL-2H3 cells was puriﬁed using TRIzol reagent
(Invitrogen). ADNA fragment containing the coding region of rat PU.1
was prepared by RT-PCR using the total RNA of RBL-2H3 as the
template with the following oligonucleotides; PU.1-For, 50-CCCCA-
CCGAAGCAGGGGATCTGACC-30, andPU.1-Rev, 50-CCGGGCG-
ACGGGTTAATGCTATGGCC-30, which corresponded to just
upstream of the translational start codon and downstream of the
translational stop codon of mouse PU.1 (Accession Nos. M32370/
M38252/NM011355 [13–15]), respectively, as primers. An RT-PCR kit
was obtained from TAKARA BIO (Otsu, Japan). PCR products wereblished by Elsevier B.V. All rights reserved.
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determined for several clones to avoid PCR errors. PCR using the same
primers was performed with a commercial rat cDNA, a Rat Liver
Marathon-Ready cDNA (Clontech, Palo Alto, CA), as a template.
2.3. Plasmid construction
For the expression of PU.1 in mammalian cells, rat PU.1 cDNA
inserted into pCR3.1 as described above was ligated into EcoRI/XhoI-
digested pCR-2F ([16] kindly provided by Dr. H. Nakano) after the
nucleotide replacements by using a QuikChange site-directed muta-
genesis kit (Stratagene, La Jolla, CA) to introduce EcoRI and XhoI
sites at just upstream of the start codon and downstream of the stop
codon of PU.1, respectively. The resulting plasmid, pCR-2F-PU.1,
directs the production of PU.1 tagged with 2Flag at N-terminus site.
The expression plasmid, pCR-GATA-1 [17,18], was also used. For the
expression of various truncated PU.1 proteins, a series of expression
plasmids, pCR-2F-PU.1-DAcid (lacking the acidic region), pCR-2F-
PU.1-DGln (lacking the Gln-rich region), pCR-2F-PU.1-DPEST
(lacking the PEST domain), and pCR-2F-PU.1-DEts (lacking the Ets
domain), were generated from pCR-2F-PU.1 as follows. To construct
pCR-2F-PU.1-DAcid, pCR-2F-PU.1-DGln, or pCR-2F-PU.1-DPEST,
PstI or SmaI site was introduced into pCR-2F-PU.1 by a QuikChange
site-directed mutagenesis kit using the following oligonucleotides and
their complements;
DAcid: 50-CCAACGTCAAACACtgcAgTACTATTCCTTGATT-30
(PstI is bold and base substitutions are small letters)
DGln: 50-GCACGTCCTTGACctgCagATGGCACCGCCCCATG-
30 (PstI is bold and base substitutions are small letters)
DPEST: 50-CCTTCTGCATGGGGcccggGGCAGCAAGAAGA-
AGA-30 (SmaI is bold and base substitutions are small letters).
By self-ligation of each mutant plasmid after PstI-digestion (DAcid
and DGln), or SmaI-digestion (DPEST), each of pCR-2F-PU.1-DAcid,
pCR-2F-PU.1-DGln, or pCR-2F-PU.1-DPEST was obtained.
To construct pCR-2F-PU.1-DEts, a DNA fragment ampliﬁed by
PCR using wild-type PU.1 as the template and 50-GCCCTGAATTC
ATGTTACAGGCGTGC-30 (EcoRI is bold) and 50-CTTCtc-
gagtCaGCCTGTCTCCCCATG-30 (XhoI is bold, stop codon is italic,
and base substitutions are small letters) as primers was introduced into
EcoRI/XhoI-digested pCR-2F after EcoRI/XhoI-digestion.
Expression plasmids of PU.1 mutants, pCR-2F-PU.1-G41S, pCR-
2F-PU.1-G41A, and pCR-2F-PU.1-S45A, were constructed as follows.
To replace Gly41 by Ser, for example, two DNA fragments were
ampliﬁed by general PCR method using pCR-2F-PU.1 as template
with primers (shown below) SDM-N plus G41S-2 and with SDM-C
plus G41S-1, respectively. These two PCR products were denatured at
94 C and annealed by cooling at room temperature. The resulting
partially double-stranded DNA was subjected to PCR using primers
SDM-N and SDM-C. The PCR product was digested with HindIII/
XbaI to replace HindIII/XbaI fragment of pCR-2F-PU.1. The fol-
lowing primers were used to construct pCR-2F-PU.1-G41A and pCR-
2F-PU.1-S45A as well as pCR-2F-PU.1-G41S.
SDM-N: 50-CTGGCTTATCGAAATTAATACGACTCACTATA-
GGG-30,
SDM-C: 50-AACAGATGGCTGGCAACTAGAAGGCACAGTC-
GAGG-30,
G41S-1: 50-CTACTATTCCTTGATTGGTAGCGATGGAGACA-
GCCATAGCG-30,
G41S-2: 50-CGCTATGGCTGTCTCCATCGCTACCAATCAAG-
GAATAGTAG-30,
G41A-1: 50-CTACTATTCCTTGATTGGTGCGGATGGAGACA-
GCCATAGCG-30,
G41A-2: 50-CGCTATGGCTGTCTCCATCCGCACCAATCAAG-
GAATAGTAG-30,
S45A-1: 50-GATTGGTGGTGATGGAGACGCGCATAGCGAT-
CACTATTGGG-30,
S45A-2: 50-CCCAATAGTGATCGCTATGCGCGTCTCCATCA-
CCACCAATC-30.
As a reporter plasmid, pGV-B2-aNN0.6 [17,18] carrying luciferase
gene under the control of human FceRI a promoter ()605/+29) was
used. Another reporter plasmid, pGV-B2-M-CSFR, was constructed
as follows. The human M-CSF receptor promoter region ()87/+72),
including repeated PU.1 motifs [19], was ampliﬁed by PCR using hu-
man genomic DNA puriﬁed from THP-1 cells (human monocyte cell
line) as the template and the following oligonucleotides as the primer
sets; 50-AGAtCtAAGATTTCCAAACTCTGTGGTTG-30 and 50-aaGCttAGAGCTCTCAGCTACTAGCTCCGCAG-30. The replaced
nucleotides to introduce BglII and HindIII sites (shown as bold), re-
spectively, are shown as small letters. The resulting DNA fragment was
introduced into BglII/HindIII-digested pGL3-Basic (Promega, Madi-
son, WI) after BglII/HindIII-digestion.
From pCR-2F-PU.1 derivatives, a fragment encoding 2Flag-tag-
ged PU.1 or its mutant was isolated and subcloned into pMX-puro
([20] moloney murine leukemia virus-based retroviral vector) by using
restriction endonucleases to generate the plasmids for expression of
PU.1 mutants, pMX-puro-PU.1-DAcid, pMX-puro-PU.1-G41S,
pMX-puro-PU.1-G41A, and pMX-puro-PU.1-S45A.
The plasmids for the expression of PU.1 mutants, pMX-puro-PU.1-
S131A, pMX-puro-PU.1-S132A, pMX-puro-PU.1-S141A, and pMX-
puro-PU.1-S147A, were constructed by site-directed mutagenesis as
described above using the following synthesized oligonucleotides.
S131A-1: 50-GTCCCCAGCCCACCAGCAGGCGTCAGATGAG-
GAGGAGGGTG-30,
S131A-2: 50-CACCCTCCTCCTCATCTGACGCCTGCTGGTGG-
GCTGGGGAC-30,
S132A-1: 50-CCAGCCCACCAGCAGAGCGCGGATGAGGAG-
GAGGGTGAG-30,
S132A-2: 50-CTCACCCTCCTCCTCATCCGCGCTCTGCTGGT-
GGGCTGG-30,
S141A-1: 50-GGAGGAGGGTGAGAGGCAGGCGCCTCCACT-
GGAGGTGTCTG-30,
S141A-2: 50-CAGACACCTCCAGTGGAGGCGCCTGCCTCTC-
ACCCTCCTCC-30.
S147A-1: 50-CCCTCCACTGGAGGTGGCGGATGGAGAAGC-
TGATG-30,
S147A-2: 50-CATCAGCTTCTCCATCCGCCACCTCCAGTGGA-
GGG-30.
2.4. Transfection and luciferase assay
U937 cells and CV-1 cells were cotransfected with a mixture of re-
porter plasmid pGV-B2-M-CSFR (5 lg), PU.1-expression plasmid (5
lg), and pRL-CMV (25 ng; Promega) as internal control. KU812 was
cotransfected with a mixture of pGV-B2-aNN0.6 (5 lg), PU.1-ex-
pression plasmid (5 lg), and pRL-CMV (25 ng) in the presence or
absence of pCR-GATA-1 (GATA-1 expression plasmid). Transfection
and luciferase assay were performed as described previously [17,18].
2.5. Transfection of bone marrow-derived cells by retrovirus vectors
Infection of bone marrow-derived cells prepared from Balb/c (Japan
SLC, Hamamatsu, Japan) was performed as follows according to the
method previously reported [10,21]. To prepare retrovirus, a series of
pMX-puro plasmids to express wild-type PU.1 and its mutants were
introduced into Plat-E [12] with Fugene6 (Roche Diagnostics, India-
napolis, IN). Culture media including the virus after 24 h- and 48
h-incubation were harvested and concentrated to 1/10 volume by
centrifugation. Bone marrow cells cultured under the previously de-
scribed conditions [10] were incubated with infectious supernatants for
2 days in the presence of 10 lg/ml of polybrene (Sigma–Aldrich). In-
fected cells were selected by cultivating in the presence of 1.2 lg/ml
puromycin for 10–20 days.
2.6. Flow cytometric analysis
Fc receptors on the cell surface were blocked with 2.4G2 (BD
PharMingen, San Diego, CA) before staining. Antibodies used were
FITC-conjugated anti-I-Ad, anti-CD11b, anti-CD11c, anti-F4/80, and
PE-conjugated anti-c-kit, all of which were purchased from BD
PharMingen. For staining of FceRI, FITC-conjugated mouse IgE (BD
PharMingen) antibodies were used. Staining and analysis by ﬂow cy-
tometry on FACSCalibur (BD) of cells were performed as described
previously [22].
2.7. Cytochemical analysis
Cells were cytocentrifuged onto glass slides and were stained by
May–Gr€unwald–Giemsa’s staining solution (Muto Pure Chemicals
Co., Ltd., Tokyo).
2.8. Western blotting analysis
Whole cells (2.5 106) from each transfectant were subjected to
Western blotting analysis. Rabbit polyclonal antibody against PU.1
(Stanta Cruz Biotechnology, Santa Cruz, CA) or mouse monoclonal
antibody against Flag-tag (Sigma–Aldrich) was used as the primary
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goat anti-mouse IgG (Molecular Probes, Inc., Eugene, OR) was used
as the secondary antibody, respectively. Infrared ﬂuorescence on
membranes was detected by Odyssey infrared imaging system (Model
ODY-9201-SC, LI-COR, Inc., Lincoln, NE).3. Results
3.1. Cloning of rat PU.1 cDNA and its nucleotide sequence
To clone rat PU.1 cDNA, we performed PCR by using two
oligonucleotides corresponding to the sequences of mouse
PU.1 cDNA as primers and cDNA prepared from RBL-2H3
cells or rat intestine cDNA as template. An ampliﬁed DNA
fragment with expected size (about 900 bp) was cloned into
pCR3.1 and several clones were sequenced. Nucleotide se-
quence of rat PU.1 cDNA and its deduced amino acid se-
quence are shown in Fig. 1. An insertion of 3 bp, which caused
a single Gln insertion between Pro15 and Pro16, was observed
in one of the ﬁve clones from RBL-2H3 and in one of the ﬁve
clones from rat intestine (Fig. 1). When cDNA sequences were
compared between PU.1s from RBL-2H3 and intestine, a
source-speciﬁc silent nucleotide substitution was found at the
third position of Thr32 codon (aca/acg) in cDNA of rat PU.1;
aca in RBL-2H3 and acg in rat intestine (see Fig. 1). Nucleo-
tide sequences of all the other portions were completely iden-
tical among the cloned fragments. The nucleotide sequence ofFig. 1. Nucleotide sequence of rat PU.1 cDNA and its deduced amino
acid sequence. The nucleotide sequence of rat PU.1 was registered in
Genbank/EMBL/DDBJ under accession number AB154364. An in-
sertion of three nucleotides resulting in addition of Gln was observed
in two from ten clones and are shown as attached boxed sequence. A
nucleotide substitution observed between cDNA prepared from RBL-
2H3 and that from rat intestine cDNA library are also boxed. All
clones have Gly as 41st residue (boxed).rat PU.1-coding region was highly homologous to those of
mouse PU.1 (93.4%) and human PU.1 (88.0%).
Alignment of amino acid sequences of rat, mouse, and hu-
man PU.1 is shown (Fig. 2A). The amino acid sequences of the
Ets domain and the Gln-rich region are extremely conserved
among rat, mouse, and human PU.1 proteins, while the amino
acid sequence of the acidic region is not so highly homologous,
compared to those of other regions. Among six Ser residues
that were suggested to be involved in the function in previous
reports (boxed with yellow in Fig. 2A), the 41st residue is re-
placed by Gly in rat PU.1, although Ser at this position is also
conserved in non-mammals, Fowl and Caiman (Fig. 2B) [23].3.2. Eﬀect of deletion of functional domains of PU.1 on the
transcription activity
To evaluate the role of the previously deﬁned regions in the
transcription-enhancing activity of PU.1, we at ﬁrst performed
a transient reporter assay for wild-type or various truncated
mutants of PU.1 using the luciferase gene under the control of
M-CSF receptor promoter that is positively regulated by PU.1
[19]. In U937 cells, M-CSF receptor promoter is known to be
activated by PMA stimulation via activation of PU.1 [24].
Consistent with the report, signiﬁcant upregulation of the
promoter activity was observed when wild-type PU.1 was co-
introduced with the reporter plasmid (Fig. 3B). Both mutants
PU.1-DGln and PU.1-DPEST lacking the Gln-rich region and
the PEST domain, respectively, possessed transactivation-en-
hancing activity no less than that of wild-type (Fig. 3B).
However, PU.1-DAcid and PU.1-DEts, lacking the acidic re-
gion and the Ets domain, respectively, possessed decreased
activities (Fig. 3B).
3.3. Eﬀect of replacement of Ser residues in acidic region on
transactivation of M-CSF receptor promoter
The above result indicates that PU.1 binds the target se-
quence by its Ets domain and exerts the ability to transactivate
the promoter by the acidic region. The acidic region contains
two Ser residues, Ser41 and Ser45, which are reported to be
involved in the function of PU.1 [8,9]. To analyze whether or
not these Ser residues are involved in the transcription activity
of PU.1, we constructed three mutants of rat PU.1, G41S,
G41A, and S45A and analyzed their promoter-transactivating
activity by transient reporter assay. As shown in Fig. 3C, all of
the three mutants possessed transactivation activity almost the
same as that of wild-type. Even when similar reporter assay
was performed in CV-1 cells, where PU.1 co-upregulates M-
CSF receptor promoter with endogenously expressed c-Jun
[24], no apparent diﬀerence was observed between the wild-
type and the mutants (Fig. 3D).3.4. Eﬀect of replacement of Ser41 and Ser45 on transcription
activity in mast cells
We have previously found that PU.1 transactivates FceRI a-
chain promoter cooperatively with GATA-1 [18]. Then, we
analyzed the transcription-enhancing activity of wild-type,
G41S, G41A, and S45A by using the a-chain/mast cell system,
to investigate whether or not Ser residues at the 41st and 45th
positions are indeed required for the cooperation with GATA-
1. The a-chain promoter was upregulated about 1.5-fold by
exogenously expressed wild-type PU.1, and no signiﬁcant dif-
ference was observed in the luciferase activity, when G41S,
Fig. 2. Amino acid alignment of PU.1. (A) Amino acid sequences of rat, mouse, and human PU.1. Each of the acidic region, the Gln rich region, the
PEST domain, and the Ets domain are boxed. Ser residues previously supposed to be important are also shown. (B) Amino acid alignment of human,
rat, mouse, fowl, and caiman PU.1 (1–50th residues) [23]. As 41st residue, Ser is conserved between human, mouse, fowl, and caiman, while Gly is
used in rat.
60 C. Nishiyama et al. / FEBS Letters 572 (2004) 57–64G41A, or S45A was overproduced in place of wild-type PU.1
(Fig. 4). The a-chain promoter was markedly upregulated,
over 40-fold, by simultaneous overproduction of GATA-1 and
wild-type PU.1. However, similar to the case with the wild-
type PU.1, all the other mutants also activated the a-chain
promoter cooperatively with GATA-1 (Fig. 4). Therefore, we
conclude that residues at 41st and 45th positions are not es-
sential for the cooperative activation of the a-chain promoter
with GATA-1.
3.5. Eﬀect of replacement of residues at 41st and 45th positions
on monocyte speciﬁc gene expression
Recently, it was reported that human CD34+ hematopoietic
progenitor cells were developed to Langerhans cells by en-
forced expression of PU.1 [25]. In addition, we recently found
that when PU.1 was overproduced by retrovirus vector in
mouse bone marrow-derived mast cell progenitors, monocyte-
speciﬁc gene expression was induced in the cells [10]. We also
found that the acidic region was critically required for the
monocyte-speciﬁc gene expression [11]. To examine the possi-
ble involvement of 41st and 45th residues in the monocyte-speciﬁc gene expression, we overproduced wild-type PU.1,
G41S, G41A, or S45A by using retrovirus system and char-
acterized development of the bone marrow-derived cells. The
progenitor overproducing wild-type PU.1, G41S, G41A, or
S45A equally expressed MHC class II, CD11b, CD11c, and
F4/80, all of which were not detected at all on surfaces of the
cells infected with the virus carrying DAcid or mock vector
(Fig. 5A). Suppression of c-kit expression was caused by
overexpression of G41S, G41A, and S45A as well as wild-type
PU.1 (Fig. 5A). Expression level of PU.1 protein in each
transfectant was analyzed by Western blotting analysis
(Fig. 5B). The level of exogenously produced PU.1 was almost
the same in every transfectant, suggesting that the proﬁle of the
cells transfected with the retrovirus carrying cDNA of PU.1-
DAcid was not due to lack or low-level production of the PU.1
mutant. Only a faint band was observed in mock transfectant
when detection was performed under overexposure condition
(bottom of Fig. 5B). These data coincide well with our previ-
ous observation [11] and indicate that the level of exogenously
produced protein is much higher than that of endogenous
PU.1 protein.
Fig. 3. Transactivation activity of PU.1 and its derivatives. (A)
Structure of wild-type or various mutants of PU.1. (B) Transactivation
activity of wild-type or truncated mutants of PU.1. U937 cells were
transfected with pGV-MCSFR and expression plasmid. Relative lu-
ciferase activity is represented as the ratio to that of pGV-MCSFR
with mock plasmid and the results are expressed as means S.E. for
more than three independent experiments in (B)–(D). (C) Eﬀect of
amino acid substitution of residues at 41st and 45th positions for the
transactivation activity. (D) PU.1 mutants, G41S, G41A, and S45A
showed almost equal degree of transactivation activity in CV-1 cells.
Fig. 4. Transactivation activity of wild-type, G41S, G41A, and S45A
PU.1 in mast cells. Reporter plasmid carrying human FceRI a-chain
promoter and PU.1-expression plasmid are transiently introduced into
KU812 cells with or without GATA-1-expression plasmid. Relative
luciferase activity is represented as the ratio to that of pGV-B2aNN0.6
with mock plasmid and the results are expressed as meansS.E. for
more than three independent experiments.
C. Nishiyama et al. / FEBS Letters 572 (2004) 57–64 61The morphology of each infected cell was analyzed by May–
Gr€unwald–Giemsa stain (Fig. 6). Control cells (infected by the
mock virus) were developed to the cells containing many
granules, which are a typical feature of mast cells. However,
overexpression of wild-type PU.1 caused a decrease in amount
of the granules and converted the cells with eccentric nucleiand polarized lamellipodia, which are monocyte-speciﬁc fea-
tures. The cells overexpressing G41S, G41A, and S45A ex-
hibited the morphology similar to that of the cells
overexpressing wild-type PU.1, while the cells overexpressing
PU.1-DAcid were developed to the cells like mast cells with
many granules.
3.6. Eﬀect of replacement of other serine residues in the PEST
domain on monocyte speciﬁc gene expression
Four additional Ser residues at 132, 133, 142, and 148
(residue numbers according to mouse and human sequences
and corresponding to 131, 132, 141, and 147 of rat sequence) in
the PEST domain are proposed to be involved in the function
of PU.1 [26,27]. To analyze the possible role of these Ser res-
idues in myeloid speciﬁc gene expression, PU.1 mutants, in
which Ser residue at 131, 132, 141, or 147 of rat PU.1 was
replaced with Ala, were overexpressed in bone marrow-derived
cells by using retrovirus system. The expression levels of
overproduced PU.1 were almost the same among transfectants
by Western blotting analysis (data not shown). All the cells
overproducing S131A, S132A, S141A, and S147A expressed
MHC class II, CD11c, CD11b, and F4/80 and gave suppressed
expression of c-kit, which was similar to the case of wild-type
PU.1 transfectant (Fig. 7), suggesting the unobvious role of
these Ser residues in monocyte-speciﬁc gene regulation.4. Discussion
Transcription factor PU.1 belonging to Ets-family is in-
volved in the development of myeloid and lymphoid cells and
regulates the transcription of many genes expressed in these
cells. PU.1 is composed of the following four functional do-
mains (regions), the acidic region, the Gln-rich region, the
PEST domain, and the Ets domain. The ﬁrst two regions, the
acidic region and the Gln-rich region, are involved in trans-
Fig. 5. Phenotype of bone marrow-derived cells transfected with retrovirus carrying wild-type or various mutant PU.1 cDNA (PU.1-DAcid, G41S,
G41A, or S45A). (A) Flow cytometric analysis of monocyte- and mast cell-speciﬁc gene expression. (B) Western blotting analysis to detect the
expression level of PU.1 proteins. Lysates (2.5 106 cells per lane) were analyzed by using anti-PU.1 (top left) or anti-Flag (top right) antibody.
Detection was also performed under overexposure condition (bottom).
Fig. 6. May–Gr€unwald–Giemsa stain of the cells cytospun, 400.
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regulation of protein degradation and interaction with other
transcription factors. The Ets domain is responsible for the
DNA-binding ability of PU.1. In the previous studies, six Ser
residues at 41, 45, 132, 133, 142, and 148 are proposed to be
involved in the function of PU.1 [26,27]. Among them, until
now, Ser at position 148 is the only residue whose function has
been deﬁnitively demonstrated [28]. In that study, Ser148 is
shown to be critical for association with IRF-4 in B cells, and
the function of PU.1 is suggested to be regulated by phos-
phorylation of Ser148. However, the involvement of other
candidate Ser residues in PU.1 function is still under contro-
versy. Celada et al. [9] proposed that Ser41 and Ser45 were
required for macrophage proliferation in response to M-CSF.
Fig. 7. Eﬀect of Ser residue replacement (S131A, S132A, S141A, and S147A) on monocyte- and mast cell-speciﬁc gene expression.
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the activation of PU.1 in response to AKT. Fisher et al. [29]
suggested that only Ser133, but not Ser41, Ser45, nor Ser148,
was required for macrophage development. Recently, Wang
et al. [27] reported that phosphorylation of PU.1 at Ser142 by
a p38 MAPK-dependent pathway was involved in the activa-
tion of PU.1. Among them, two Ser residues, Ser41 and Ser45,
in the acidic region have been presumed to be the most
probable residues that are involved in function and its regu-
lation of PU.1 protein [8,9]. In the present study, we have
found that rat PU.1 possesses Gly but not Ser residue at po-
sition 41. This indicates that Ser41 is not essential for function
at least in rat PU.1. In this study, we analyzed transcription
activity of wild-type or mutants of PU.1 in various systems;
transactivation of M-CSFR promoter, cooperative transacti-
vation with GATA-1, and induction of monocyte-speciﬁc gene
expression and morphological change in bone marrow-derived
mast cell progenitors. All of the mutant rat PU.1 proteins,
G41S, G41A, and S45A, possessed the activities comparable to
those of wild-type in all assay systems. Thus, all our results
were negative in requirement of Ser41 and Ser45 for the
function of PU.1. Considering that the acidic region was
critically required for the function of PU.1 (Figs. 3, 5 and 6),
we may assume that other residues are responsible for the
function, though they have not yet been analyzed. Interest-
ingly, the homology of the amino acid sequence in the acidic
region is considerably lower than other regions (Fig. 2). Fur-
ther analysis using the retrovirus transfection and reporter
assay systems used in this study will provide useful informa-
tion on the residues critical for the transactivation function of
PU.1.Rat PU.1 mutant S147A (corresponding to S148A of mouse
and human PU.1) lacks a critical Ser residue whose phosphor-
ylation is essential for interaction with IRF-4 [28]. In this study,
Ala-replacement of four Ser residues in the PEST domain,
Ser131, Ser132, Ser141, and Ser147 (residue numbers are ac-
cording to rat PU.1 sequence and corresponding to Ser132,
Ser133, Ser142, and Ser147 of mouse and human sequences),
did not aﬀect the function of PU.1 as a transactivator. We
previously reported that overproduction of PU.1-mutant lack-
ing the PEST domain also induced the expression of monocyte-
speciﬁc gene, such as MHC class II, CD11c, CD11b, and F4/80
[11], indicating that the PEST domain has no apparent function
in our assay systems. Therefore, no obvious eﬀect of Ala-re-
placement at Ser131, Ser132, Ser141, or Ser147 in the PEST
domain found in the present study is quite reasonable. PU.1 is
capable of regulating the target genes by binding to its cognate
DNA site by itself, while PU.1 is required to form a heterodimer
with IRF-4 to activate Igj 30 gene expression [30]. Therefore, the
present result suggests that PU.1 functions to upregulate the
expression of the monocyte-speciﬁc genes without forming a
heterodimer with IRF-4 at least in our assay system.
Various stimulation signals such as colony-stimulating fac-
tors, PMA, and LPS, all of which are capable of inducing my-
eloid diﬀerentiation, are suggested to be transduced to their
targets via PU.1 activation [31–34]. It has been reported that
stimulation by LPS caused phosphorylation of Ser residues of
PU.1 to induce conformational change of the transcription
factor suitable for controlling gene expression [32]. Further-
more, by thePMA-stimulationnovel slow-migratingPU.1-DNA
complex(s) was observed in EMSA [31,33], and PU.1 some-
times exhibited diﬀerent mobility in SDS–PAGE depending
64 C. Nishiyama et al. / FEBS Letters 572 (2004) 57–64on the cell lines used as the source of PU.1 [35]. These
observations indicate that PU.1 is regulated by post-transcrip-
tional modiﬁcation. Further analysis using various PU.1 mu-
tants, which possess amino acid substitution other than the 41st
and 45th residues in the acidic region, will be required to de-
termine the residues essential for regulating the functions of
PU.1. Especially, function of PU.1 mutants, in which all the Ser
residues in the acidic region are replaced by Ala, should be an-
alyzed in the near future. Until now, three-dimensional struc-
tural information of PU.1 was available only for its DNA-
binding Ets domain. Therefore, determination of three-dimen-
sional structure of whole PU.1 molecule could provide useful
information to elucidate the regulatory mechanism of PU.1.
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